INTEGRATING MOLECULAR BIOLOGY WITH CANCER MOLECULAR IMAGING AND THERANOSTICS

将分子生物学与癌症分子成像和治疗诊断学相结合

• 批准号: 10323750
• 负责人: Balaji Krishnamachary
• 金额: $ 9.34万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-23 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10323750
• 关键词: Award; Doctor of Philosophy; Environment; Funding; Gene Silencing; Genes; Genetic Transcription; Goals; Grant; Hypoxia; Hypoxia Inducible Factor; In Vitro; Laboratory Research; Malignant Neoplasms; Mentors; Methods; Mission; Molecular; Molecular Biology; Molecular Biology Techniques; Monitor; Neoplasm Metastasis; Pathology; Postdoctoral Fellow; Productivity; Renal carcinoma; Research; Research Personnel; Research Project Grants; Small Interfering RNA; Specialist; Talents; Training; Work; cancer imaging; career; hypoxia inducible factor 1; in vivo Cellular and Molecular Imaging Centers; medical schools; molecular imaging; nanoparticle delivery; pediatric department; post-doctoral training; programs; recruit; small hairpin RNA; theranostics; tumor; tumor microenvironment; tumor progression

Y at ha A hu Vai ryo The purpose of this R50 application is to provide 6 months effort for Dr. Balaji Krishnamachary as a Research Specialist working with Dr. Bhujwalla as Unit Director. Dr. Krishnamachary was awarded his PhD in 1995, following which he completed his postdoctoral training, first in the Department of Pathology at ULCA from 1998- 2000, and subsequently in the Department of Pediatrics at Johns Hopkins School of Medicine from 2000-2006. During his postdoctoral training in the Department of Pediatrics, Dr. Krishnamachary worked with Dr. Gregg Semenza on hypoxia and the hypoxia inducible factor (HIF)-1. He gained significant expertise in constructing both siRNA and shRNA, establishing a retroviral delivery method to silence the transcription factor hypoxia inducible factor-1 (HIF-1) in vitro in renal carcinoma, and was trained in various molecular biology techniques to interrogate the transcriptional activity of genes involved in the progression of cancer. Dr. Krishnamachary joined Dr. Bhujwalla’s Cancer Imaging Research Program in 2006 as a Research Associate. Dr. Krishnamachary is a laboratory research-oriented investigator with an outstanding track record in integrating molecular biology with molecular imaging and theranostics. As an exceptionally talented molecular biologist who has been actively pursuing research within Dr. Bhujwalla’s NCI funded molecular imaging and theranostics research program, this opportunity is particularly relevant for Dr. Krishnamachary. He has shown clear evidence of productivity and research excellence in molecular biology applied to molecular imaging. Dr. Krishnamachary will continue to integrate his molecular biology expertise within the cancer molecular imaging research program directed by Dr. Bhujwalla, with the goal of making significant contributions to cancer molecular imaging that is relevant to the NCI mission. The Unit Director, Dr. Bhujwalla, has been funded continuously by the NCI since 1997. Dr. Krishnamachary was recruited by her in 2006 to provide molecular biology expertise to her molecular imaging research program following the funding of an NCI P50 grant (JHU ICMIC Program) that she held from 2003-2017. Dr. Bhujwalla currently holds an NCI R35 Outstanding Investigator Award on ‘Molecular Imaging and Theranostics of Cancer’ that is funded until 2024. Since the previous R50 submission, Dr. Bhujwalla competitively renewed her R01 titled ‘Hostile Environments promote Invasion and Metastasis’, and was awarded a new R01 on ‘The Tumor Microenvironment in Nanoparticle Delivery and Function’. Dr. Krishnamachary’s efforts are closely integrated and critical to the scientific research of these grants providing clear evidence that Dr. Bhujwalla is strongly committed to Dr. Krishnamachary and his research. She has worked closely with Dr. Krishnamachary since 2006 and will continue to be responsible for the planning, direction, monitoring, and execution of the NCI funded research together with Dr. Krishnamachary. Dr. Bhujwalla’s purpose in supporting this application to the best of her ability is to achieve a stable environment for Dr. Krishnamachary and to advance his career.

一哈一胡八凉 此R50申请的目的是为Balaji Krishnamachary博士提供6个月的研究工作 与Bhujwalla博士一起工作的专家，作为单位主任。Krishnamachary博士于1995年获得博士学位， 之后，他完成了博士后培训，首先从1998年开始在ULCA病理学系- 2000年，随后在约翰霍普金斯医学院儿科从2000-2006年。 在他的儿科博士后培训期间，Krishnamachary博士与Gregg博士一起工作， Semenza对缺氧和缺氧诱导因子（HIF）-1的影响。他获得了重要的专业知识， siRNA和shRNA，建立了一种逆转录病毒递送方法来沉默转录因子缺氧 诱导因子-1（HIF-1）在肾癌中的体外研究，并接受了各种分子生物学技术的培训， 询问参与癌症进展的基因的转录活性。 博士Krishnamachary于2006年加入Bhujwalla博士的癌症成像研究计划，担任研究助理。 博士Krishnamachary是一位实验室研究型的调查员，在整合 分子生物学、分子成像和治疗诊断学。作为一位才华横溢的分子生物学家， 一直在Bhujwalla博士的NCI资助的分子成像和治疗诊断学中积极进行研究 研究计划，这个机会是特别相关的克里希那玛切里博士。他有明确的证据 在分子生物学应用于分子成像的生产力和研究卓越。克里希那玛切里博士 将继续将他的分子生物学专业知识融入癌症分子成像研究计划 由Bhujwalla博士指导，目标是为癌症分子成像做出重大贡献， 与国家癌症研究所的使命有关 自1997年以来，该股股长Bhujwalla博士一直得到国家癌症研究所的资助。Krishnamachary博士 2006年被她招募，为她的分子成像研究项目提供分子生物学专业知识 在2003-2017年获得NCI P50赠款（JHU ICMIC计划）后，她获得了资助。布瓦拉博士 目前拥有NCI R35杰出研究者奖“分子成像和癌症治疗” 这一计划将持续到2024年。自上一次提交R50以来，Bhujwalla博士竞争性地更新了她的R 01， “敌对环境促进侵袭和转移”，并在“肿瘤”上获得了新的R 01 微环境在纳米粒子的交付和功能。克里希那玛切里博士的努力与 这些赠款的科学研究提供了明确的证据，表明布瓦拉博士强烈 致力于克里希那玛切里博士和他的研究她一直与克里希那玛切里博士密切合作， 2006年，并将继续负责规划，指导，监督和执行国家癌症基金会资助的 与Krishnamachary博士一起研究。Bhujwalla博士尽最大努力支持本申请的目的 她的能力是为克里希那玛切里博士创造一个稳定的环境，并推动他的事业。